MyFinsight
Home
Blog
About
Contact
Download
Download image
Net change in cash
and cash...
-$4,662,817
Accrued expenses
$19,538,657
Stock-based compensation
expense
$3,526,710
Accounts receivable, net
of allowances
-$2,970,056
Amortization of in-process
research and development
$1,720,312
Prepaid expenses
-$110,553
Net cash (used in)
provided by operating...
-$3,831,618
Net cash used in
investing activities
-$600,000
Net cash provided by
financing activities
-$231,199
Canceled cashflow
$27,866,288
Net loss
-$26,609,695
License payments
$600,000
Deferred financing costs
$169,252
Net proceeds from
issuance of common stock
-$61,947
Due to related party
-$3,273,092
Accounts payable
-$1,563,661
Deferred income tax
expense
-$231,210
Inventory
$20,248
Back
Back
Cash Flow
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)
source: myfinsight.com